Pelthos Therapeutics (PTHS) Total Current Liabilities (2022 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Total Current Liabilities of $26.0 million for Q4 2025, up 536.62% year-over-year from $4.1 million in Q4 2024, and up 4.95% quarter-over-quarter from $24.8 million in Q3 2025.
Pelthos Therapeutics (PTHS) Total Current Liabilities (2022 - 2026) Analysis & Trends
Pelthos Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $26.0 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 536.62% year-over-year to $26.0 million; the TTM figure through Dec 2025 stood at $26.0 million (up 536.62% YoY), while the FY2025 annual figure was $26.0 million, up 536.62% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $26.0 million, up from $24.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $26.0 million in Q4 2025, with the low at $2.8 million in Q2 2024.
- The 4-year median for Total Current Liabilities is $4.6 million (2024), against an average of $8.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities tumbled 37.58% in 2024, then surged 594.29% in 2025.
- Pelthos Therapeutics' Total Current Liabilities stood at $3.8 million in 2022, then soared by 73.89% to $6.5 million in 2023, then sank by 37.58% to $4.1 million in 2024, then jumped by 536.62% to $26.0 million in 2025.
- Business Quant data shows PTHS's Total Current Liabilities at $26.0 million in Q4 2025, $24.8 million in Q3 2025, and $7.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | Pelthos Therapeutics | 92.20 Mn | 67.64 Mn | 21.23 Mn | 31.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.96 Mn |
| Dec 31, 2025 | 25.99 Mn |
| Sep 30, 2025 | 24.77 Mn |
| Jun 30, 2025 | 7.32 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 6.54 Mn |
| Dec 31, 2022 | 3.76 Mn |